Class 1a Antiarrythmics has 2 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Pimavanserin, Pimavanserin Tartrate. Patients taking Class 1a Antiarrythmics should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Major: 2

Major (2)

Class 1a Antiarrythmics + Pimavanserin— Concomitant use may add to QT prolongation effects of pimavanserin and increase risk of cardiac arrhythmia.
Class 1a Antiarrythmics + Pimavanserin Tartrate— Concomitant use may add to QT prolongation effects and increase risk of cardiac arrhythmia.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.